Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encore Pharmaceuticals Inc.

http://www.encorepharma.com

Latest From Encore Pharmaceuticals Inc.

Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals

Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.

Deals M & A

Best of the Blog: IN VIVO, June 2008

In May, Windhover's editorial staff posted 35 articles to the blog, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Here are a few of our favorite posts that didn't make it into stories covered elsewhere in this month's magazine: Changing of the Change Agents: Exit Wyeth's Ruffolo, Enter Orbimed's Dolsten; Cimzia Launch: Nothing Simple About It; Lundbeck Thanks Myriad For the Memories; Takeda's Millions Buy a Lot of Beer.

Deal Statistics Quarterly, Q2 2004

Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.

BioPharmaceutical Medical Device

The Proteomic Evolution of Celera, Incyte and Myriad

Impatient with the progress of genomics, investors are looking to a new set of proteomics technologies to provide the necessary boost in research productivity. Celera, Incyte, and Myriad, the heads of which we interview in this article, have each created widely different strategies for accessing the new opportunities. Aside from differences in technology approaches, the strategies of all three firms attempt to directly address the investment world's dissatisfaction with platform models-the original business model of both Incyte and Celera. Myriad has taken a low-risk leap into the world of proteomics, spinning off its proteomics tools into a new database company that will map the proteome, delivering Myriad the information it needs for its own product discovery and development programs and selling it at the same time on a non-exclusive basis to subscribers.Celera is radically modifying its information-only strategy, transforming itself into a drug discovery company that will be assisted financially with proceeds from its database business, which will itself be boosted by new proteomic data Celera will create, review before others, and then make available to subscribers. Incyte is continuing to focus on selling information as its base business, but is adding proteomic features to its basic systems through acquisition and internal development. At the same time, it is trading access to its LifeSeq database to new proteomic technology developers for a share either of their downstream product revenues and/or rights to sell the information those products generate.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register